Home・Aandelen Lijst・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Gesloten

SectorGezondheidszorg

110.45 0.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

108.05

Max

111.61

Belangrijke statistieken
By Trading Economics
Inkomsten	18M -69M
Verkoop	32M 34M
EPS	-0.71
Winstmarge	-201.467
Werknemers	253
EBITDA	18M -67M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+17.84% upside

Dividenden
By Acuity
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2.1B 9.1B
Vorige openingsprijs	110.07
Vorige sluitingsprijs	110.45

Nieuwssentiment

By Acuity

50%

163 / 340 Rangschikking in Healthcare

Kymera Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21 jul 2026, 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20 jul 2026, 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Peer Vergelijking

Prijswijziging

Kymera Therapeutics Inc Prognose

Koersdoel

By TipRanks

17.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 130.07 USD 17.84%

Hoogste 155 USD

Laagste 115 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kymera Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Gebaseerd op 16 analisten die aandelenratings hebben gegeven aan Kymera Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

163 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.